Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributor.authorSuvaporn Anugulruengkitten_US
dc.contributor.authorTim R. Cresseyen_US
dc.contributor.authorPiyarat Suntarattiwongen_US
dc.contributor.authorPradthana Ounchanumen_US
dc.contributor.authorUssanee Srirompotongen_US
dc.contributor.authorWatsamon Jantarabenjakulen_US
dc.contributor.authorJiratchaya Sophonphanen_US
dc.contributor.authorYardpiroon Tawonen_US
dc.contributor.authorSunti Punnahitanonen_US
dc.contributor.authorChitsanu Pancharoenen_US
dc.contributor.authorKulkanya Chokephaibulkiten_US
dc.contributor.authorThanyawee Puthanakiten_US
dc.description.abstractBACKGROUND: Triple-drug infant antiretroviral prophylaxis containing nevirapine (NVP) is increasingly used to prevent HIV transmission among neonates at high risk of HIV infection. Our aim was to describe NVP concentration from birth through the first month of life. METHODS: High-risk HIV-exposed neonates were enrolled in a prospective cohort in Thailand. High-risk neonates defined as maternal HIV RNA >50 copies/mL before delivery or mother received antiretroviral treatment for <12 weeks before delivery. Neonates received zidovudine (4 mg/kg) and lamivudine (2 mg/kg) twice daily, plus NVP (4 mg/kg) once daily (no lead-in) from birth to 6 weeks of life. Infant plasma samples were collected at 1, 2, 14 or 2, 7, 28 days of life. NVP trough concentrations (C24) were estimated using a population pharmacokinetic model and target C24 was ≥0.1 mg/L. "Washout" efavirenz (EFV) concentrations were assessed in infants whose mother received EFV-based antiretroviral treatment. RESULTS: A total of 48 infants were included: 25 (52%) were male and 12 (25%) were preterm (gestational age 34-37 weeks). Median (interquartile range) predicted NVP C24 were 1.34 mg/L (1.13-1.84), 2.24 (2.00-2.59), 2.78 (2.61-3.12), 2.20 (1.86-2.44) and 0.81 (0.58-0.98) on days 1, 2, 7, 14 and 28 of life, respectively. NVP C24 was not significantly different between term and preterm infants. All infants maintained NVP C24 ≥0.1 mg/L. EFV via placental transfer remained detectable in infants up to 7 days of life. CONCLUSIONS: NVP 4 mg/kg daily from birth provided adequate prophylactic concentrations during the first month of life in high-risk HIV-exposed neonates.en_US
dc.titleNevirapine Concentrations During the First Month of Life and Maternal Efavirenz Washout in High-Risk HIV-Exposed Infants Receiving Triple Antiretroviral Prophylaxisen_US
article.title.sourcetitleThe Pediatric infectious disease journalen_US
article.volume38en_US the Departments of Pediatricsen_US Universityen_US Mai Universityen_US School of Public Healthen_US of Liverpoolen_US Sirikit National Institute of Child Healthen_US Prachanukroh Hospitalen_US Kaen Regional Hospitalen_US HIV Netherlands Australia Thailand Research Collaborationen_US Universityen_US
Appears in Collections:CMUL: Journal Articles

Files in This Item:
There are no files associated with this item.

Items in CMUIR are protected by copyright, with all rights reserved, unless otherwise indicated.